Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Influx Healthtech Ltd
Quarter-by-quarter operating performance
Financials of Influx Healthtech Ltd
Annual income statement trend
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales + | 0 | 59 | 76 | 100 | 105 | 147 |
| Expenses + | 0 | 53 | 65 | 83 | 84 | 117 |
| Operating Profit | 0 | 6 | 11 | 17 | 21 | 30 |
| OPM % | 11% | 14% | 17% | 20% | 20% | |
| Other Income + | 0 | 0 | 0 | 0 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 1 | 2 | 3 | 4 |
| Profit before tax | 0 | 6 | 10 | 15 | 18 | 27 |
| Tax % | 26% | 26% | 25% | 25% | 25% | |
| Net Profit + | 0 | 4 | 7 | 11 | 13 | 21 |
| EPS in Rs | 0.00 | 1,800.00 | 2,880.00 | 4,452.00 | 7.37 | 8.87 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Financials of Influx Healthtech Ltd
Capital structure and asset base
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.03 | 0.03 | 0.03 | 0.03 | 18 | 23 |
| Reserves | 0 | 4 | 12 | 23 | 18 | 78 |
| Borrowings + | 0 | 1 | 1 | 0 | 0 | 0 |
| Other Liabilities + | -0 | 12 | 16 | 18 | 34 | 23 |
| Total Liabilities | 0 | 18 | 28 | 41 | 70 | 124 |
| Fixed Assets + | 0 | 3 | 6 | 14 | 19 | 28 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 2 |
| Other Assets + | 0 | 15 | 22 | 27 | 52 | 90 |
| Total Assets | 0 | 18 | 28 | 41 | 70 | 124 |
Financials of Influx Healthtech Ltd
Operating, investing and financing cash movement
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 0 | 4 | 7 | 9 | 7 | 4 |
| Cash from Investing Activity + | 0 | -3 | -5 | -8 | -9 | -25 |
| Cash from Financing Activity + | 0 | 1 | 0 | -1 | -0 | 45 |
| Net Cash Flow | 0 | 1 | 2 | 0 | -2 | 23 |
| Free Cash Flow | 0 | 1 | 2 | 1 | -1 | -21 |
| CFO/OP | 89% | 87% | 70% | 56% | 41% |
Financials of Influx Healthtech Ltd
Working capital efficiency and return ratios
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 64 | 66 | 58 | 113 | 84 | |
| Inventory Days | 14 | 18 | 41 | 112 | 67 | |
| Days Payable | 88 | 123 | 106 | 248 | 80 | |
| Cash Conversion Cycle | -10 | -39 | -6 | -24 | 71 | |
| Working Capital Days | 2 | 1 | 15 | 46 | 83 | |
| ROCE % | 237% | 111% | 85% | 60% | 40% |
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…